New predictive biomarkers for plasma leakage in dengue fever

Using two complementary high-throughput proteomics platforms on early febrile phase plasma samples, researchers identified 23 differentially expressed proteins, many of liver origin, that serve as potential early predictive biomarkers for dengue-associated plasma leakage.

The Gist

Imagine the human body as a bustling city with a complex network of roads (blood vessels) and a central power plant (the liver). When a dangerous virus like Dengue invades, it's like a sudden, chaotic storm hitting the city.

For most people, the city's emergency services handle the storm just fine. But for about one-third of patients, the storm causes a catastrophic failure: the roads start leaking, and vital fluids escape into the surrounding neighborhoods. In medical terms, this is plasma leakage, the hallmark of severe Dengue that can lead to shock and death.

The problem is that doctors currently have no "weather forecast" to predict who is going to have this disaster. They only know the roads are leaking after the flood has already started, which is often too late to save the patient.

This paper is like a team of high-tech detectives trying to find the early warning signs of that flood before it happens.

The Detective Work: Two Different Tools

Instead of just looking at one clue, the researchers used two different, high-powered "microscopes" to scan the blood of 222 patients who had just started getting sick with Dengue.

1. Tool A (LC-MS/MS): A heavy-duty scanner that weighs and identifies proteins like a sophisticated scale.
2. Tool B (SomaScan): A smart net that catches thousands of specific protein "fish" using tiny molecular hooks.

By using both tools, they ensured that any clue they found wasn't just a glitch or a mistake. They were looking for the same "smoke signals" appearing in both sets of data.

The Big Discovery: 23 Early Warning Signals

The detectives found 23 specific proteins that acted as a "canary in the coal mine." These proteins were present in the blood of patients who later developed severe plasma leakage, but were missing or different in patients who stayed mild.

Think of these 23 proteins as 23 different smoke alarms going off in the city's power plant before the fire even starts.

Here is what the clues tell us, using some simple analogies:

• The Liver is the Hero (and the Victim):
  Shockingly, 14 out of the 23 of these warning signals come from the liver.

  • The Analogy: Imagine the city's power plant (the liver) starts overheating and spewing smoke before the roads (blood vessels) even start leaking. This suggests that the liver is one of the first places to go into crisis mode during severe Dengue. If we can monitor the liver's "smoke," we can predict the flood.

• The Road Crew is Panicking:
  Several proteins found were related to the "construction crew" that builds and repairs the roads (the blood vessel walls).

  • The Analogy: In a healthy city, the road crew is calm. In these patients, the crew is frantically trying to patch holes and rebuild walls, but they are doing it in a chaotic, disorganized way. This tells us the roads are already weak and about to give way.

• The Alarm System is Blaring:
  Other proteins were part of the body's immune "alarm system" (like STAT3 and ISG15).

  • The Analogy: It's like the fire department is screaming "FIRE!" so loudly that the noise itself is causing panic and chaos in the city, making the situation worse. The body is overreacting to the virus, and that overreaction is what causes the leakage.

Why This Matters

Currently, when a patient walks into a hospital with Dengue, doctors have to guess: "Will this person get better on their own, or will their blood vessels start leaking in two days?" It's like driving blindfolded.

This study provides a predictive map. If a doctor could test for these 23 proteins in the first few days of a fever, they could say:

"This patient has the 'smoke alarms' going off. Even though they look okay right now, their liver is struggling and their blood vessels are about to leak. We need to move them to intensive care now."

The Catch

The researchers are careful to say this is a preliminary discovery. They found the clues, but they haven't built the final "detector" yet.

• The Limitation: They used a "pooled" method (mixing blood from many people together) to find the general pattern. It's like listening to a choir to hear the melody, but you can't hear the individual singers yet.
• The Next Step: They need to test these 23 proteins on individual patients to prove they work as a reliable "early warning system" for everyone, not just the groups they studied.

The Bottom Line

This paper is a major step forward in turning Dengue treatment from a game of "wait and see" into a game of "predict and prevent." By listening to the liver and the immune system's early whispers, we might soon be able to stop the flood before it ever starts.

Technical Summary

1. Problem Statement

• Clinical Challenge: Plasma leakage is the defining pathophysiological hallmark of severe dengue, occurring in 35–38% of symptomatic cases. It typically manifests 5–7 days after fever onset, following peak viraemia.
• Current Limitations: There are currently no validated early predictive biomarkers available during the "early febrile phase" (first 96 hours) to distinguish patients who will develop plasma leakage from those who will not.
• Consequence: This lack of early prediction leads to unnecessary hospitalizations and missed opportunities for timely intervention, particularly in resource-limited settings where clinical capacity is strained.
• Research Gap: Previous proteomic studies have been fragmentary, often relying on single platforms, focusing on general infection markers rather than leakage-specific signatures, and lacking cross-validation.

2. Methodology

The study employed a dual-platform, high-throughput proteomic discovery strategy to ensure robustness and broad coverage.

• Cohort & Study Design:

  • Source: Data derived from the Colombo Dengue Study (CDS), a prospective observational cohort in Sri Lanka (2017–2020).
  • Participants: 278 total individuals, including:
    • 222 confirmed dengue patients (stratified by subsequent development of plasma leakage [PL+] vs. non-leakage [PL-]).
    • 50 non-dengue febrile patients (controls).
    • 6 healthy controls.
  • Stratification: Dengue patients were further categorized by prior exposure (Primary vs. Secondary infection) and leakage status.
  • Sample Pooling: To minimize inter-individual variability while maintaining statistical power, plasma samples were pooled (50 individuals per pool) into 7 distinct categories.
  • Inclusion Criteria: Patients recruited within 96 hours of fever onset; no plasma leakage at enrolment; exclusion of chronic comorbidities (diabetes, CVD, liver/kidney disease).

• Proteomic Platforms:

  1. LC-MS/MS: Liquid chromatography–tandem mass spectrometry with high-abundance protein depletion.
  2. SomaScan: Aptamer-based profiling targeting ~11,000 proteins.
  • Note: Both platforms were applied to the same pooled samples to identify cross-validated biomarkers.

• Statistical Analysis:

  • Differential Expression: Performed using the limma package (R v4.2.2).
  • Thresholds:
    • LC-MS/MS: Log2 fold change (FC) ≥ 1, p ≤ 0.05.
    • SomaScan: Log2 FC ≥ 0.2, p ≤ 0.05 (adjusted for non-linear aptamer response).
  • Validation Criteria: Only proteins consistently up- or down-regulated across both platforms were considered final biomarkers.
  • Subgroup Analysis: Separate analyses conducted for Primary vs. Secondary dengue infections.

3. Key Results

• Discovery Scale:

  • LC-MS/MS detected 1,358 proteins; SomaScan detected 9,665 targets.
  • 910 proteins were detected by both platforms.
  • Main Analysis (PL+ vs. PL-):
    • LC-MS/MS identified 108 differentially expressed proteins (DEPs).
    • SomaScan identified 3,181 DEPs.
    • Cross-Validation: 23 proteins were consistently differentially expressed across both platforms, serving as the core predictive biomarker panel.

• The 23 Biomarkers:

  • Direction: 20 were upregulated in PL+ patients; 3 were downregulated.
  • Liver Enrichment: 14 of the 23 proteins are highly expressed in the liver, suggesting early hepatic dysfunction is central to plasma leakage.
  • Key Proteins Identified:
    • Upregulated: STAT3, ISG15, HSP90AB1, COL3A1, PHGDH, MAT1A, CPS1, PSG7, PSG9, H4C1 (Histone H4), SRGN, DPYS, CBR4, PSME2, HAPLN3, RPS16, CYB5A, ILF3, PA2G4, STAT1.
    • Downregulated: S100P, CSRP1, SPINK5.

• Subgroup Findings (Primary vs. Secondary):

  • Secondary Dengue: Showed a wider overlap with the main analysis (15/23 detected by SomaScan, 11/23 by LC-MS/MS).
  • Universal Predictors: Five proteins (ISG15, STAT3, COL3A1, ILF3, PHGDH) were detected in both primary and secondary infections by at least one platform, suggesting they may serve as universal predictors regardless of immune history.
  • Strongest Candidates: ISG15 and STAT3 were detected by both platforms in secondary dengue and by SomaScan in primary dengue.

4. Functional Insights & Mechanisms

Functional analysis of the 23 biomarkers revealed convergent roles in four key biological pathways:

1. Endothelial Dysfunction & Vascular Integrity:
   • COL3A1 (Collagen) and HAPLN3 (Matrix stabilization) indicate extracellular matrix remodeling.
   • S100P, CSRP1, SPINK5 downregulation suggests impaired endothelial homeostasis and cytoskeletal dynamics.
   • H4C1 (Histone) upregulation links to Neutrophil Extracellular Traps (NETs) and vasculopathy.
2. Immune Dysregulation:
   • Upregulation of STAT1, STAT3, and ISG15 points to heightened interferon signaling and NF-κB pathways, driving inflammation.
   • PSG7/PSG9 (Pregnancy-specific glycoproteins) suggest immune modulation.
3. Metabolic Reprogramming:
   • PHGDH (Serine biosynthesis), MAT1A (Methionine metabolism), and CPS1 (Urea cycle) highlight metabolic shifts, particularly in the liver, potentially driving anti-inflammatory M2 macrophage polarization or antiviral responses.
4. Cellular Stress & Protein Degradation:
   • HSP90AB1 (Chaperone) and PSME2 (Proteasome activator) indicate cellular stress responses and increased proteasomal activity.

5. Significance and Conclusion

• Novelty: This is the first study to apply a dual-platform proteomic strategy specifically to identify early predictors of plasma leakage, moving beyond general dengue severity markers.
• Clinical Impact: The identified 23 biomarkers offer a potential roadmap for developing point-of-care prognostic tools. Early identification of leakage risk could optimize hospital admission criteria and resource allocation in endemic regions.
• Pathophysiological Insight: The findings strongly implicate early hepatic dysfunction and metabolic reprogramming as drivers of plasma leakage, challenging the view that leakage is solely a result of late-stage immune hyperactivation.
• Limitations & Future Work:
  • The study relied on sample pooling, which may mask low-abundance protein variability.
  • The cohort had an equal mix of primary/secondary dengue, which may not reflect real-world demographics (often skewed toward secondary in adults).
  • Next Steps: These biomarkers require quantitative validation in independent, individual-level cohorts to confirm generalizability and predictive utility before clinical implementation.

Conclusion: The study successfully identifies a robust panel of 23 cross-validated proteins that signal early disruption of immune, metabolic, and structural pathways preceding plasma leakage in dengue, with a distinct signature of early liver involvement.